STOCK TITAN

[8-K] First Advantage Corporation Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Davidson Kempner affiliates disclose a near-maximum 9.9% passive stake in Biora Therapeutics (BIOR). On 30 Jun 2025 the hedge-fund complex — M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP and Managing Member Anthony A. Yoseloff — filed Amendment No. 1 to Schedule 13G.

  • Total beneficial ownership: up to 906,227 common shares (including 851,177 issuable on note conversion), representing 9.90 % of BIOR’s 4,552,702 outstanding shares.
  • Structure: All voting and dispositive power is shared; none of the entities have sole power.
  • Convertible notes: 91 % of the reported position is in notes convertible into equity, but conversions are capped by a 9.90 % blocker, limiting immediate dilution.
  • M.H. Davidson & Co. separately lists 25,624 shares (0.56 %) including 24,033 from notes.
  • The group certifies the position is passive (Rule 13d-1(c)) and not intended to influence control.

The disclosure signals a sizable institutional bet on BIOR while highlighting potential dilution from convertible securities, though the blocker tempers near-term ownership expansion.

Le affiliate di Davidson Kempner dichiarano una partecipazione passiva quasi massima del 9,9% in Biora Therapeutics (BIOR). Il 30 giugno 2025 il gruppo hedge fund — M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP e il socio gestore Anthony A. Yoseloff — ha presentato l'Emendamento n. 1 al Modulo 13G.

  • Partecipazione totale: fino a 906.227 azioni ordinarie (inclusi 851.177 azioni emesse tramite conversione di note), pari al 9,90% delle 4.552.702 azioni in circolazione di BIOR.
  • Struttura: Tutti i poteri di voto e dispositivi sono condivisi; nessuna entità detiene potere esclusivo.
  • Note convertibili: Il 91% della posizione dichiarata è costituito da note convertibili in azioni, ma le conversioni sono limitate da un blocco al 9,90%, riducendo la diluizione immediata.
  • M.H. Davidson & Co. segnala separatamente 25.624 azioni (0,56%), di cui 24.033 derivanti da note.
  • Il gruppo certifica che la posizione è passiva (Regola 13d-1(c)) e non è finalizzata a influenzare il controllo.

La comunicazione indica una significativa scommessa istituzionale su BIOR, evidenziando al contempo la possibile diluizione dalle obbligazioni convertibili, anche se il blocco limita l'espansione della proprietà nel breve termine.

Las filiales de Davidson Kempner revelan una participación pasiva casi máxima del 9,9% en Biora Therapeutics (BIOR). El 30 de junio de 2025, el grupo de fondos de cobertura — M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP y el miembro gerente Anthony A. Yoseloff — presentaron la Enmienda Nº 1 al Formulario 13G.

  • Propiedad total beneficiaria: hasta 906,227 acciones comunes (incluyendo 851,177 emitidas mediante conversión de notas), que representan el 9,90 % de las 4,552,702 acciones en circulación de BIOR.
  • Estructura: Todo el poder de voto y disposición es compartido; ninguna entidad tiene poder exclusivo.
  • Notas convertibles: El 91 % de la posición reportada está en notas convertibles en acciones, pero las conversiones están limitadas por un bloqueo del 9,90 %, lo que limita la dilución inmediata.
  • M.H. Davidson & Co. lista por separado 25,624 acciones (0,56 %), incluyendo 24,033 provenientes de notas.
  • El grupo certifica que la posición es pasiva (Regla 13d-1(c)) y no está destinada a influir en el control.

La divulgación señala una apuesta institucional considerable en BIOR, destacando al mismo tiempo la posible dilución por valores convertibles, aunque el bloqueo modera la expansión inmediata de la propiedad.

데이비드슨 켐프너 계열사는 Biora Therapeutics(BIOR)에 대해 거의 최대치인 9.9%의 수동적 지분을 공시했습니다. 2025년 6월 30일, 헤지펀드 그룹인 M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP 및 매니징 멤버 Anthony A. Yoseloff가 Schedule 13G 수정안 1호를 제출했습니다.

  • 총 실질 소유: 최대 906,227 보통주(전환사채로 발행 가능한 851,177주 포함)로 BIOR의 4,552,702 발행 주식의 9.90%에 해당합니다.
  • 구조: 모든 의결권 및 처분 권한은 공유되며; 어느 단체도 단독 권한을 갖지 않습니다.
  • 전환사채: 보고된 포지션의 91%가 주식으로 전환 가능한 사채에 해당하지만, 9.90% 제한 장치(blocker)로 인해 즉각적인 희석은 제한됩니다.
  • M.H. Davidson & Co.는 별도로 25,624주(0.56%)를 보고하며, 이 중 24,033주는 전환사채에서 나왔습니다.
  • 그룹은 이 지분이 수동적(Rule 13d-1(c))이며, 지배권에 영향을 미치려는 의도가 없음을 인증합니다.

이번 공시는 BIOR에 대한 상당한 기관 투자 배팅을 나타내며, 전환 증권으로 인한 희석 가능성을 강조하지만, 제한 장치가 단기 소유권 확대를 억제합니다.

Les filiales de Davidson Kempner révèlent une participation passive proche du maximum de 9,9 % dans Biora Therapeutics (BIOR). Le 30 juin 2025, le groupe de fonds spéculatifs — M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP et le membre gérant Anthony A. Yoseloff — a déposé l’amendement n° 1 au formulaire 13G.

  • Propriété bénéficiaire totale : jusqu’à 906 227 actions ordinaires (dont 851 177 issues de la conversion de billets), représentant 9,90 % des 4 552 702 actions en circulation de BIOR.
  • Structure : Tous les pouvoirs de vote et de disposition sont partagés ; aucune entité ne détient de pouvoir exclusif.
  • Billets convertibles : 91 % de la position déclarée concerne des billets convertibles en actions, mais les conversions sont limitées par un seuil de blocage à 9,90 %, ce qui restreint la dilution immédiate.
  • M.H. Davidson & Co. déclare séparément 25 624 actions (0,56 %), dont 24 033 provenant de billets.
  • Le groupe certifie que la position est passive (règle 13d-1(c)) et n’est pas destinée à influencer le contrôle.

Cette déclaration signale un pari institutionnel important sur BIOR tout en soulignant un risque potentiel de dilution lié aux titres convertibles, bien que le seuil de blocage limite l’expansion de la propriété à court terme.

Davidson Kempner-Tochtergesellschaften geben eine nahezu maximale passive Beteiligung von 9,9 % an Biora Therapeutics (BIOR) bekannt. Am 30. Juni 2025 reichte der Hedgefonds-Komplex – M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP und der geschäftsführende Gesellschafter Anthony A. Yoseloff – Änderung Nr. 1 zum Formular 13G ein.

  • Gesamtwirtschaftliches Eigentum: bis zu 906.227 Stammaktien (einschließlich 851.177 aus der Umwandlung von Wandelanleihen), was 9,90 % der 4.552.702 ausstehenden BIOR-Aktien entspricht.
  • Struktur: Alle Stimm- und Verfügungsrechte werden geteilt; keine der Einheiten besitzt Alleinmacht.
  • Wandelanleihen: 91 % der gemeldeten Position bestehen aus in Aktien wandelbaren Anleihen, wobei die Umwandlungen durch eine 9,90 %-Blockade begrenzt sind, was eine sofortige Verwässerung einschränkt.
  • M.H. Davidson & Co. meldet separat 25.624 Aktien (0,56 %), davon 24.033 aus Wandelanleihen.
  • Die Gruppe bestätigt, dass die Position passiv ist (Regel 13d-1(c)) und nicht darauf abzielt, die Kontrolle zu beeinflussen.

Die Offenlegung signalisiert eine bedeutende institutionelle Wette auf BIOR und weist gleichzeitig auf eine mögliche Verwässerung durch Wandelanleihen hin, wobei die Blockade eine kurzfristige Eigentumsausweitung begrenzt.

Positive
  • Institutional validation: A well-known hedge fund complex committing up to 9.9 % of BIOR may boost market confidence and liquidity.
Negative
  • Potential dilution: 851,177 shares are issuable from convertible notes, creating an overhang once the 9.9 % blocker constraint eases.

Insights

TL;DR – Hedge fund holds 9.9 % via notes, signalling confidence but creating convertible overhang.

Davidson Kempner’s 906 k-share exposure (almost entirely via convertibles) equals the legal ownership ceiling. For a micro-cap with <5 m shares outstanding, this stake is material, adding a sophisticated investor whose interests align with share appreciation. However, the heavy use of notes foreshadows dilution once the blocker lapses or if the base increases. Investors should track any future 13D moves that could indicate an activist tilt.

TL;DR – Passive filing limits immediate governance impact; monitor for 13D shift.

The Schedule 13G confirms Davidson Kempner is currently passive, mitigating control-change risk. Shared voting rights across entities concentrate influence in Yoseloff, but the 9.9 % cap prevents majority leverage. Should the fund re-file on Schedule 13D, governance dynamics could change rapidly, especially in light of convertible note triggers.

Le affiliate di Davidson Kempner dichiarano una partecipazione passiva quasi massima del 9,9% in Biora Therapeutics (BIOR). Il 30 giugno 2025 il gruppo hedge fund — M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP e il socio gestore Anthony A. Yoseloff — ha presentato l'Emendamento n. 1 al Modulo 13G.

  • Partecipazione totale: fino a 906.227 azioni ordinarie (inclusi 851.177 azioni emesse tramite conversione di note), pari al 9,90% delle 4.552.702 azioni in circolazione di BIOR.
  • Struttura: Tutti i poteri di voto e dispositivi sono condivisi; nessuna entità detiene potere esclusivo.
  • Note convertibili: Il 91% della posizione dichiarata è costituito da note convertibili in azioni, ma le conversioni sono limitate da un blocco al 9,90%, riducendo la diluizione immediata.
  • M.H. Davidson & Co. segnala separatamente 25.624 azioni (0,56%), di cui 24.033 derivanti da note.
  • Il gruppo certifica che la posizione è passiva (Regola 13d-1(c)) e non è finalizzata a influenzare il controllo.

La comunicazione indica una significativa scommessa istituzionale su BIOR, evidenziando al contempo la possibile diluizione dalle obbligazioni convertibili, anche se il blocco limita l'espansione della proprietà nel breve termine.

Las filiales de Davidson Kempner revelan una participación pasiva casi máxima del 9,9% en Biora Therapeutics (BIOR). El 30 de junio de 2025, el grupo de fondos de cobertura — M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP y el miembro gerente Anthony A. Yoseloff — presentaron la Enmienda Nº 1 al Formulario 13G.

  • Propiedad total beneficiaria: hasta 906,227 acciones comunes (incluyendo 851,177 emitidas mediante conversión de notas), que representan el 9,90 % de las 4,552,702 acciones en circulación de BIOR.
  • Estructura: Todo el poder de voto y disposición es compartido; ninguna entidad tiene poder exclusivo.
  • Notas convertibles: El 91 % de la posición reportada está en notas convertibles en acciones, pero las conversiones están limitadas por un bloqueo del 9,90 %, lo que limita la dilución inmediata.
  • M.H. Davidson & Co. lista por separado 25,624 acciones (0,56 %), incluyendo 24,033 provenientes de notas.
  • El grupo certifica que la posición es pasiva (Regla 13d-1(c)) y no está destinada a influir en el control.

La divulgación señala una apuesta institucional considerable en BIOR, destacando al mismo tiempo la posible dilución por valores convertibles, aunque el bloqueo modera la expansión inmediata de la propiedad.

데이비드슨 켐프너 계열사는 Biora Therapeutics(BIOR)에 대해 거의 최대치인 9.9%의 수동적 지분을 공시했습니다. 2025년 6월 30일, 헤지펀드 그룹인 M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP 및 매니징 멤버 Anthony A. Yoseloff가 Schedule 13G 수정안 1호를 제출했습니다.

  • 총 실질 소유: 최대 906,227 보통주(전환사채로 발행 가능한 851,177주 포함)로 BIOR의 4,552,702 발행 주식의 9.90%에 해당합니다.
  • 구조: 모든 의결권 및 처분 권한은 공유되며; 어느 단체도 단독 권한을 갖지 않습니다.
  • 전환사채: 보고된 포지션의 91%가 주식으로 전환 가능한 사채에 해당하지만, 9.90% 제한 장치(blocker)로 인해 즉각적인 희석은 제한됩니다.
  • M.H. Davidson & Co.는 별도로 25,624주(0.56%)를 보고하며, 이 중 24,033주는 전환사채에서 나왔습니다.
  • 그룹은 이 지분이 수동적(Rule 13d-1(c))이며, 지배권에 영향을 미치려는 의도가 없음을 인증합니다.

이번 공시는 BIOR에 대한 상당한 기관 투자 배팅을 나타내며, 전환 증권으로 인한 희석 가능성을 강조하지만, 제한 장치가 단기 소유권 확대를 억제합니다.

Les filiales de Davidson Kempner révèlent une participation passive proche du maximum de 9,9 % dans Biora Therapeutics (BIOR). Le 30 juin 2025, le groupe de fonds spéculatifs — M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP et le membre gérant Anthony A. Yoseloff — a déposé l’amendement n° 1 au formulaire 13G.

  • Propriété bénéficiaire totale : jusqu’à 906 227 actions ordinaires (dont 851 177 issues de la conversion de billets), représentant 9,90 % des 4 552 702 actions en circulation de BIOR.
  • Structure : Tous les pouvoirs de vote et de disposition sont partagés ; aucune entité ne détient de pouvoir exclusif.
  • Billets convertibles : 91 % de la position déclarée concerne des billets convertibles en actions, mais les conversions sont limitées par un seuil de blocage à 9,90 %, ce qui restreint la dilution immédiate.
  • M.H. Davidson & Co. déclare séparément 25 624 actions (0,56 %), dont 24 033 provenant de billets.
  • Le groupe certifie que la position est passive (règle 13d-1(c)) et n’est pas destinée à influencer le contrôle.

Cette déclaration signale un pari institutionnel important sur BIOR tout en soulignant un risque potentiel de dilution lié aux titres convertibles, bien que le seuil de blocage limite l’expansion de la propriété à court terme.

Davidson Kempner-Tochtergesellschaften geben eine nahezu maximale passive Beteiligung von 9,9 % an Biora Therapeutics (BIOR) bekannt. Am 30. Juni 2025 reichte der Hedgefonds-Komplex – M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP und der geschäftsführende Gesellschafter Anthony A. Yoseloff – Änderung Nr. 1 zum Formular 13G ein.

  • Gesamtwirtschaftliches Eigentum: bis zu 906.227 Stammaktien (einschließlich 851.177 aus der Umwandlung von Wandelanleihen), was 9,90 % der 4.552.702 ausstehenden BIOR-Aktien entspricht.
  • Struktur: Alle Stimm- und Verfügungsrechte werden geteilt; keine der Einheiten besitzt Alleinmacht.
  • Wandelanleihen: 91 % der gemeldeten Position bestehen aus in Aktien wandelbaren Anleihen, wobei die Umwandlungen durch eine 9,90 %-Blockade begrenzt sind, was eine sofortige Verwässerung einschränkt.
  • M.H. Davidson & Co. meldet separat 25.624 Aktien (0,56 %), davon 24.033 aus Wandelanleihen.
  • Die Gruppe bestätigt, dass die Position passiv ist (Regel 13d-1(c)) und nicht darauf abzielt, die Kontrolle zu beeinflussen.

Die Offenlegung signalisiert eine bedeutende institutionelle Wette auf BIOR und weist gleichzeitig auf eine mögliche Verwässerung durch Wandelanleihen hin, wobei die Blockade eine kurzfristige Eigentumsausweitung begrenzt.

False000121067700012106772025-07-302025-07-30

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 30, 2025

 

 

First Advantage Corporation

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-31666

84-3884690

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1 Concourse Parkway NE

Suite 200

 

Atlanta, Georgia

 

30328

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (678) 868-4151

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

FA

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 1.01. Entry into a Material Definitive Agreement.

On July 30, 2025, First Advantage Holdings, LLC ( the “Borrower”), an indirect subsidiary of First Advantage Corporation, entered into Amendment No. 5 (“Amendment No. 5”) to the first lien credit agreement dated as of January 31, 2020 (as amended, the “Credit Agreement”) among Fastball Parent, Inc., First Advantage Holdings, LLC, the lenders from time to time party thereto and Bank of America, N.A., as administrative agent, collateral agent and the issuing banks party thereto from time to time.

Among other items, Amendment No. 5 (i) reduced the interest rate on the term loan facility due October 31, 2031 by 0.50% to a range of 2.50% to 2.75%, based on the first lien ratio, plus SOFR and (ii) reduced the interest rate on the $250.0 million revolving credit facility due October 31, 2029 by 0.50% to a range of 2.25% to 2.75%, based on the first lien ratio, plus SOFR.

The summary of the Credit Agreement is subject to, and qualified in its entirety by reference to, Amendment No. 5 (and the annexed conformed Credit Agreement), which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated in this Item 2.03 by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

 

Description

10.1

 

Amendment No. 5 to the First Lien Credit Agreement, among Fastball Parent, Inc., First Advantage Holdings, LLC, each lender from time to time party thereto, Bank of America, N.A., as Administrative Agent and Collateral Agent and the issuing banks party thereto from time to time, dated July 30, 2025.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

FIRST ADVANTAGE CORPORATION

 

 

 

 

Date:

August 4, 2025

By:

/s/ Steven Marks

 

 

 

Name: Steven Marks
Title: Executive Vice President & Chief Financial Officer

 


FAQ

How much of Biora Therapeutics (BIOR) does Davidson Kempner own?

The group reports beneficial ownership of up to 906,227 shares, or 9.90 % of outstanding common stock.

What is the composition of the reported BIOR stake?

Approximately 91 % of the position comes from notes convertible into common shares; the remainder is currently outstanding stock.

Does the filing indicate activist intent toward BIOR?

No. The Schedule 13G filing and certification state the securities are held for passive investment purposes.

What is the 9.90 % blocker mentioned in the filing?

The notes prohibit conversion that would push the group’s ownership above 9.90 %, limiting immediate voting power and dilution.

Could the convertible notes dilute existing BIOR shareholders?

Yes. If and when the blocker is lifted or the share count rises, 851,177 additional shares could enter the market.
First Advantage Corp

NASDAQ:FA

FA Rankings

FA Latest News

FA Stock Data

2.86B
78.16M
3.41%
106.52%
5.93%
Specialty Business Services
Services-computer Processing & Data Preparation
Link
United States
ATLANTA